d Dr. Jung-Chi Liao founded SYNCELL in 2020 with the optoproteomics technology invented in his lab at Academia Sinica in Taiwan. Under his guidance, the SYNCELL team is advancing the Microscoop product development and business strategy to realize SYNCELL’s vision to become a dominant player in spatial omics. Dr. Liao takes a precision synergy approach to create a cooperative and efficient culture suitable for multidisciplinary communication. Having been immersed in the high-tech spinoff environment at MIT, Cal Berkeley, Stanford, and Columbia, he shapes SYNCELL to match the high caliber and advance toward a leading global life science equipment company.

From 2003 to 2008, Lucy was Vice President of the US Chief Technology Officer at Roche Diagnostics. In her early career, Lucy focused on drug development at Genentech and BMS, before switching to marketing at Applied Biosystems to market novel life science instruments and reagents.” to “From 2003 to 2008, Lucy was Vice President of the US Chief Technology Office at Roche Diagnostics. In her early career, Lucy focused on drug development at Genentech and BMS before switching to marketing at Applied Biosystems to market novel life science instruments and reagents.

Yi-De Chen is a co-inventor of Syncell’s Microscoop system. As the VP Technology, he is responsible for leading all the R&D technical development, including optics, mechatronics, software, chemistry, and biology applications. Prior to joining Syncell, he dedicated seven years to the invention and development of the Microscoop optoproteomics and image-guided photolabeling technology.

During this formative period, he has developed strong technical expertise and interdisciplinary R&D management experiences to successfully drive the prototype system development across all functions. Yi-De holds an MS degree in chemistry from National Taiwan University and a BS degree in physics from Soochow University.

Ya-Lan Hsieh has been serving as Vice President of Administration since the inception of Syncell in May 2020. At Syncell, she oversees human resources, finance, licensing/contracts, and office management. Prior to joining Syncell, Ya-Lan served as the General Manager of Taiwan Biobank, where she successfully built and scaled the whole operation to build the largest biorepository and database with annotated genetic, environmental, and clinical information of local population. During her 14-year career at Taiwan Biobank, her leadership and operational excellence helped lay a solid foundation for biomedical research and clinical investigations in Taiwan.

Ya-Lan holds an MS degree from Institute of Biomedical Sciences of National Sun Yat-Sen University and a BS degree in Public Health from China Medical College.

With over three decades of experience in the field of biotechnology, Daniel has focused on the commercialization of new products, techniques, and technologies, specifically in the areas of genomics, proteomics, epigenomics, single cell analysis, and bioinformatics. He has worked in companies of all sizes, ranging from small teams of seven employees to large organizations with over 40,000 employees. As a strategic thinker, he is passionate about developing people, exploring new markets, and nurturing key accounts.
Prior to joining Syncell, Daniel served as the VP of Global Sales at various companies such as, Ionpath, BioDiscovery, Active Motif, Gentel Biosciences and NimbleGen. He has successfully established multiple worldwide commercial teams and distribution networks. He has previously held leadership roles in several large companies such as, PerkinElmer, Fluidigm, Roche and Invitrogen.

Dr. Martin Madaus has 30+ years’ experience in biotechnology, diagnostics, and pharma industry. He is currently Chairman of Quanterix, Senior Healthcare Operating Executive of the Carlyle Group, and a Board Member of Standard Biotools, Repligen, Unchained Labs, Emulate Bio, and Syntis Bio. Previously, Dr. Madaus served as President, Chairman, and CEO of Millipore, when Millipore was acquired by Merck KGaA. He also served as President and CEO of Roche Diagnostics North America, Chairman and CEO of Ortho-Clinical Diagnostics, CEO and President of Quanterix, and a Board Member of Mettler Toledo. Dr. Madaus received a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany.

Dr. Don Kania has 25+ years of experience in life science technology, biotechnology, and photonics industries. He is currently Chairman of Gandeeva Therapeutics and a Board Member of Intuitive Surgical and Lumicks BV. Previously, Dr. Kania served as CEO and President of FEI Company, a high-performance electron microscopy company, until its acquisition by Thermo Fisher. He also served as President and COO of Veeco Instruments, and a Board Member of DNA Script, Nanostring, Aldevron, and American Science and Engineering Inc. Dr. Kania held technical and management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory. He received his PhD from the University of Michigan.

Dr. W. E. Moerner is the Harry S. Mosher Professor of Chemistry and Professor by courtesy of Applied Physics at Stanford University. He has conducted research in physical chemistry, biophysics, and the optical properties of single molecules, and is actively involved in the development of 2D and 3D super-resolution imaging for cell biology, including protein superstructures in bacteria, cells, and studies of chromatin organization, and dynamics of regulatory proteins in the primary cilium. His research uses single molecule spectroscopy and powerful microscopes optimized for tracking of single biomolecules in cells, and measures the motions of proteins, DNA, and RNA in three dimensions in real time to study biological processing, binding interactions and molecular dynamics.
Among many other honors and awards, Professor Moerner was elected fellow of the American Physical Society, Optical Society of America, American Association for the Advancement of Science, American Academy of Arts and Sciences, member of the National Academy of Sciences, and was recognized with the 2014 Nobel Prize in Chemistry "for the development of super-resolved fluorescence microscopy."

Dr. Yang is Chair Professor of National Taiwan University. He is former president of National Taiwan University and member of Academia Sinica, World Academic of Science and the National Academy of Inventors. His research interests are lung cancer genomics and precision cancer therapy. He is actively involved in developing novel strategies, including multi-omics, aptamer, nanotechnology and siRNA to improve diagnosis and therapy for cancer and infectious diseases, including COVID-19. His team recently by proteogenomics revealed distinct genetic and environmental signatures of lung cancer pathogenesis and progression in never-smokers. He received the 2020 IASLC Joseph W. Cullen Distinguished Award because of the contributions in leading the lung cancer screening and improving the survival of lung cancer patients.

Dr. Peter K. Jackson is a Professor in the Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, at the Stanford University. Between 1995 and 2005, he was a faculty at Stanford University School of Medicine and was involved in the studies of cell cycle biochemistry, regulation of the cancer by kinases and phosphatases, the ubiquitin-proteasome system, and the discovery of a new physiological class of competitive (“pseudosubstrate”) E3 ubiquitin ligase inhibitors, exemplified by the APC/C regulator Emi1.
He became a Staff Scientist at Genentech in 2005. At Genentech, he helped define and implement the development of therapeutics for cancer pathways including cell cycle checkpoints, stress pathways, and tumor metabolism. In 2013, he returned to Stanford University and has been focusing on signaling through the primary cilium, using proteomic approaches to define regulatory networks and new disease genes to create molecular signatures for diagnostics and therapeutic development.
He has received many awards and honors for his distinguished research, including awards from the Baxter Foundation, Howard Hughes Medical Institute, the American Cancer Society, the Pluto Society, and being a Stanford Hume Faculty Scholar and a Kirsch Scholar, and was elected a Fellow of the American Association for the Advancement of Science in 2008.